|
Subject: Effectiveness
and Tolerability of FDC of 0.15% Brimonidine/ 0.5%Timolol
compared to FDC of 0.2% Brimonidine/0.5% Timolol for the
Treatment of Primary Open Angle Glaucoma or Ocular Hypertension
in a Real World Setting: A Retrospective Analysis.
Glaucoma is the leading cause of irreversible blindness in world. It is estimated to affect >70 million people worldwide, 10% of whom are blind in both eyes. The prevalence of glaucoma is expected to nearly double from 2013 to 2040 in the scenario of a rapidly growing and aging population. Medical therapy for glaucoma is considered a mainstay of treatment. A great number of patients with primary open-angle glaucoma require combination therapy to efficiently compensate the IOP and prevent further development of glaucoma. There are several potential benefits of fixed dose combination (FDC) medications compared with using the individual components separately. These include a reduction in the total number of drops and preservative instilled per day, cost savings, improved tolerability and compliance.
This retrospective analysis aims to evaluate effectiveness and tolerability of FDC of 0.15% Brimonidine/ 0.5%Timolol compared to FDC of 0.2% Brimonidine/0.5% Timolol for the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in a Real World Setting: A Retrospective Analysis.
We invite you to participate in this study and share your experience in 10 consecutive patients with open-angle glaucoma or ocular hypertension (to avoid any bias) in whom you have prescribed FDC of 0.15% Brimonidine/ 0.5%Timolol or FDC of 0.2% Brimonidine/0.5% Timolol in the normal course of practice. Thus, this is not an experimental/interventional study.
If you agree to participate, requesting you to copy the relevant information from the patient’s case papers, and investigational reports if any (which we call source documents), on to the standard data collection forms (which we call DCF). A personnel will assist you in verifying the DCF with the source documents to ensure that the DCF signed by you are free from errors or omissions. Let us assure you that the DCF will not contain the patient’s names so as to ensure confidentiality.
As you will be spending some extra time to keep, copy and verify these patients records, we offer to pay you by cheque a professional fee of Rs. {{$contractAmount}}, and accordingly on receiving the completed CRFs of number of patients that has been suggested to you.
We trust you and we are partners in promoting safe effective medical therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}